Mintz Mark, Legoff Daniel, Scornaienchi Jean, Brown Micah, Levin-Allen Sarah, Mintz Pnina, Smith Cathy
Clinical Research Center of New Jersey and The Center for Neurological and Neurodevelopmental Health, Voorhees, New Jersey 08043, USA.
J Child Neurol. 2009 Jul;24(7):807-15. doi: 10.1177/0883073808330762. Epub 2009 Feb 2.
The purpose of this prospective, open-label pilot study was to determine whether treatment with levetiracetam improves neuropsychological functioning in children and adolescents who have evidence of subclinical spike production associated with attention and learning difficulties. Six participants (mean age 9.8 years) were treated with levetiracetam up to 40 mg/kg per day and evaluated using neuropsychological (Wide Range Assessment of Memory and Learning, Second Edition), academic (Wechsler Individual Achievement Test, Second Edition, Abbreviated), and electroencephalographic assessments at baseline and after 10 weeks of treatment. Statistically significant improvements on indexes of the Wide Range Assessment of Memory and Learning, Second Edition were observed in 4 participants after 10 weeks. No statistically significant differences were observed for the Wechsler Individual Achievement Test, Second Edition, Abbreviated. Concomitant spike suppression was observed. Levetiracetam was generally well tolerated. A subset of patients exists with attention and learning problems that have associated aberrant cortical electrical activity without clinical seizures and associated neuropsychological deficits that may improve after treatment with levetiracetam.
这项前瞻性、开放标签的试点研究旨在确定，对于有与注意力及学习困难相关的亚临床棘波产生证据的儿童和青少年，左乙拉西坦治疗是否能改善其神经心理功能。6名参与者（平均年龄9.8岁）接受了每日最高40毫克/千克的左乙拉西坦治疗，并在基线及治疗10周后使用神经心理评估（《广泛记忆与学习评估第二版》）、学业评估（《韦氏个别成就测验第二版简版》）和脑电图评估进行评价。10周后，4名参与者在《广泛记忆与学习评估第二版》各项指标上有统计学显著改善。在《韦氏个别成就测验第二版简版》中未观察到统计学显著差异。同时观察到棘波抑制现象。左乙拉西坦总体耐受性良好。存在一部分有注意力和学习问题的患者，他们伴有异常的皮层电活动但无临床癫痫发作，且伴有神经心理缺陷，使用左乙拉西坦治疗后可能会改善。
